
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CKR-7 CRISPR/Cas9 KO Plasmid (h) | sc-402150 | 20 µg | $397.00 | |||
CKR-7 HDR Plasmid (h) | sc-402150-HDR | 20 µg | $445.00 |
CCR7 (CKR-7) is a G protein–coupled chemokine receptor that binds CCL19 and CCL21 to control directional migration and positioning of immune cells within secondary lymphoid tissues. Signaling through CCR7 activates downstream pathways such as PI3K–AKT, MAPK, and small GTPase networks that coordinate chemotaxis, actin remodeling, and integrin-dependent adhesion. CCR7 is central to dendritic cell trafficking to lymph nodes and T cell recirculation, shaping antigen presentation and immune surveillance. Dysregulated CCR7 expression or signaling is frequently studied in the context of chronic inflammation, autoimmune phenotypes, and tumor cell dissemination where chemokine-guided migration contributes to disease biology.
CKR-7 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the CCR7 gene in human cell lines. Each plasmid in the pool co-expresses a unique sgRNA, targeting a distinct site within the CCR7 locus, alongside the Streptococcus pyogenes Cas9 nuclease, and encodes GFP to enable fluorescent identification and enrichment of successfully transfected cells. This multi-guide strategy increases the likelihood of inducing frameshifts or deletions that produce a functional knockout, offering a more robust alternative to single-guide approaches. DSBs induced at multiple sites are resolved through non-homologous end joining (NHEJ) or, when used with the included HDR donor template, homology-directed repair (HDR) at a defined target site within the locus.
When used in conjunction with the RFP-expressing HDR donor, GFP and RFP fluorescence can be used together to distinguish transfected from edited cell populations, streamlining flow cytometry-based sorting and clone selection workflows.
For applications requiring confirmed, selectable knockout clones, CKR-7 HDR Plasmid (h) includes an HDR donor construct containing a puromycin resistance cassette (PuroR) and a red fluorescent protein (RFP) reporter, flanked by homology arms specific to a defined CCR7 target site.
When co-transfected with CKR-7 CRISPR/Cas9 KO Plasmid (h):
The HDR donor construct features loxP sites flanking the PuroR-RFP selection cassette to allow clean marker removal following clone confirmation. Transient expression of Cre recombinase via the included Cre Vector: sc-418923 excises the cassette, leaving a minimal residual loxP site within the CCR7 locus and eliminating potential confounding effects on downstream assays.
This two-step approach:
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.